Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR1 | P32241 | 3/20 | 0.53 |
| ▸ | VIPR2 | P41587 | 4/20 | 0.50 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.50 |
| ▸ | GLP1R | P43220 | 2/20 | 0.50 |
| ▸ | TFPI | P10646 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 2/20 | 0.49 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30752382 | 1.00 | VIPR1 (0.53) | VIPR1VIPR2KISS1RGRIN2DGRIN3B | |
| SCHEMBL29907889 | 1.00 | VIPR1 (0.53) | VIPR1VIPR2KISS1RGRIN2DGRIN3B | |
| SCHEMBL30752379 | 0.99 | VIPR1 (0.55) | VIPR1VIPR2KISS1RGLP1RBACE1 | |
| SCHEMBL31622476 | 0.99 | VIPR1 (0.55) | VIPR1VIPR2KISS1RGLP1RBACE1 | |
| SCHEMBL31622480 | 0.99 | VIPR1 (0.52) | VIPR1VIPR2KISS1RGRIN2DGRIN3B | |
| SCHEMBL30618090 | 0.99 | VIPR1 (0.52) | VIPR1VIPR2KISS1RGRIN2DGRIN3B | |
| SCHEMBL30752385 | 0.98 | VIPR1 (0.52) | VIPR1VIPR2KISS1RGRIN2DGRIN3B | |
| SCHEMBL30752387 | 0.98 | VIPR1 (0.52) | VIPR1VIPR2KISS1RGRIN2DGRIN3B | |
| SCHEMBL30712758 | 0.97 | VIPR1 (0.50) | VIPR1VIPR2KISS1RGRIN2DGRIN3B | |
| SCHEMBL15669773 | 0.95 | TFPI (0.53) | VIPR1VIPR2KISS1RGRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722236-A1 | INSULIN DERIVATIVE AND USE THEREOF | The United Bio-Technology (Hengqin) Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| EP-4623900-A2 | METHODS AND COMPOSITIONS FOR THE PREVENTION OF TYPE 1 DIABETES | Dr. Mary Morris & Associates, LLC (US) | 2025-10-01 | — | — | EP | disclosed |
| US-12410228-B2 | Insulin analogs | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-09-09 | — | — | US | disclosed |
| CN-119454911-A | Compositions comprising long acting insulin analogue conjugates and long acting insulinotropic peptide conjugates for treating diabetes | 韩美药品株式会社 | 2025-02-18 | — | — | CN | disclosed |
| WO-2024239961-A1 | INSULIN DERIVATIVE AND USE THEREOF | 联邦生物科技(珠海横琴)有限公司 | 2024-11-28 | — | — | WO | disclosed |
| CN-114989289-B | Novel insulin analogues and uses thereof | 韩美药品株式会社 | 2024-10-01 | — | — | CN | disclosed |
| CN-117487026-A | insulin-Fc fusion protein and application thereof | 江苏晟斯生物制药有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-110339369-B | Improved process for preparing physiologically active polypeptide complexes | 韩美科学株式会社 | 2024-01-23 | — | — | CN | disclosed |
| CN-117337299-A | Molecular design of glucose responsive insulin analogue glucose sensor | 印地安纳大学理事会 | 2024-01-02 | — | — | CN | disclosed |
| CN-117242098-A | Conformationally constrained glucagon analogs and their use in glucagon-single chain insulin fusion proteins | 印地安纳大学理事会 | 2023-12-15 | — | — | CN | disclosed |
| EP-4230216-A1 | INSULIN-FC FUSION PROTEIN AND APPLICATION THEREOF | Jiangsu Gensciences Inc. (CN) | 2023-08-23 | — | — | EP | disclosed |
| CN-110072884-B | Insulin analogues | 犹他大学研究基金会 | 2023-07-28 | — | — | CN | disclosed |
| US-20220340636-A1 | INSULIN ANALOGS | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2022-10-27 | — | — | US | disclosed |
| US-20220288213-A1 | INSULIN ANALOGUES WITH GLUCOSE REGULATED CONFORMATIONAL SWITCH | THERMALIN INC (US) | 2022-09-15 | — | — | US | disclosed |
| WO-2022125587-A9 | ACYLATED SINGLE-CHAIN INSULIN ANALOGUES | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022125587-A1 | ACYLATED SINGLE-CHAIN INSULIN ANALOGUES | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-06-16 | — | — | WO | disclosed |
| EP-4007594-A1 | PREMIXED ULTRA-STABLE SINGLE-CHAIN INSULIN ANALOGUE FORMULATIONS | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11248034-B2 | Insulin analogs | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2022-02-15 | — | — | US | disclosed |
| WO-2022017309-A1 | INSULIN-FC FUSION PROTEIN AND APPLICATION THEREOF | 江苏晟斯生物制药有限公司 | 2022-01-27 | — | — | WO | disclosed |
| CN-113968911-A | insulin-Fc fusion protein and application thereof | 江苏晟斯生物制药有限公司 | 2022-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288213-A1 | INSULIN ANALOGUES WITH GLUCOSE REGULATED CONFORMATIONAL SWITCH | IAPP, GPR119, INSR | VIPR1 328/4885VIPR2 434/4885KISS1R 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.